-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
<>
The funds raised in the C round will be used to further strengthen Zhenge Bio’s global R&D center and expand its production capacity in compliance with Good Manufacturing Practice (GMP) to meet the needs of domestic and foreign customers
Zhenge Bio provides one-stop contract R&D and manufacturing (CDMO) services to help customers discover, develop and manufacture biopharmaceuticals by providing end-to-end solutions from concept to commercialization
Zhenge Bio has integrated advanced cell culture platforms, metabolite analysis platforms, recombinant protein analysis platforms and customized medium pilot production platforms for customers to help customers improve unit yield and quality
In addition to R&D centers in Shanghai and Maryland, U.
Zhenge Bio takes environmental, social and governance (ESG) responsibility as an integral part of its corporate strategy.
Chen Jianxin, Chairman and CEO of Zhenge Bio, said: "We are delighted to be led by top international investment institutions such as Goldman Sachs Asset Management, Sofina and Novo Holdings in this round of financing, and thank them for their recognition and support of Zhen Ge Bio.
Xu Xiaoou, Managing Director of Goldman Sachs Asset Management, said: "The global biopharmaceutical market is huge and developing rapidly.
Lv Xiaotian, Head of SOFINA China, and Lin Yizhen, Investment Manager, said: "We are delighted to support Zhenge Bio
Dr.
About Goldman Sachs Asset Management Growth Equity
Goldman Sachs Asset Management integrates traditional and alternative investment businesses, serves clients globally and focuses on long-term performance
About Sofina
Sofina is a Brussels Stock Exchange listed, family-owned and operated investment company
About Novo Holdings
Novo Holdings is a private limited liability company wholly owned by the Novo Nordisk Foundation
Novo Holdings is recognized as a leading international life sciences investor focused on creating long-term value
Shanghai Zhenge Biotechnology Co.
